Agoracom Blog Home

Posts Tagged ‘cannabinoids’

Avicanna Inc. $AVCN.ca to Host Second Quarter 2020 Investor Conference Call $CRDL.ca $PCLO.ca $WEED.ca $ACB.ca

Posted by AGORACOM-JC at 6:46 PM on Friday, August 7th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

TORONTO, Aug. 7, 2020 – Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that it has scheduled a conference call on Monday, August 17, 2020 at 9:00AM Eastern Time to discuss the results for its fiscal second quarter ended June 30, 2020. Aras Azadian, Chief Executive Officer and Davender Sohi, Chief Financial Officer, will host the call and a question and answer period. The Company will report its financial results for the second quarter after the close of markets on Friday, August 14, 2020.

            Conference Call Details

DATE:                                           August 17, 2020                                   
TIME:  9:00 AM Eastern Time
  
CONFIRMATION #:                             64751998
  
TORONTO:                                           416-764-8659
NORTH AMERICAN TOLL FREE:         1-888-664-6392
GERMANY TOLL FREE:   08007240293
COLOMBIA TOLL FREE:      018005184036
  
REPLAY TORONTO:                             416-764-8677  
REPLAY NORTH AMERICA:    1-888-390-0541 
REPLAY ENTRY CODE:   751998#
REPLAY EXPIRATION DATE:               August 24, 2020

About Avicanna Inc.

Avicanna is an Ontario, Canada based corporation focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products through its two main business segments, cultivation and research and development.

Avicanna’s two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia are the base for Avicanna’s cultivation activities. These two companies are licensed to cultivate and process cannabis for the production of cannabis extracts and purified cannabinoids including cannabidiol (CBD) and tetrahydrocannabinol (THC).

Avicanna’s research and development business is primarily conducted out of Canada at its headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto. Avicanna’s scientific team develops products, and Avicanna has also engaged the services of researchers at the Leslie Dan Faculty of Pharmacy at the University of Toronto for the purpose of optimizing and improving upon its products.

Avicanna’s research and development and cultivation activities are focused on the development of its key products, including plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics, and Extracts (defined as plant-derived cannabinoid extracts and purified cannabinoids, including distillates and isolates), with a goal of eventually having these products manufactured and distributed through various markets.

Stay Connected

For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email at [email protected].

Cautionary Note Regarding Forward-Looking Information and Statements

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These forward-looking statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions, estimates and assumptions of management in light of management’s experience and perception of historical trends, current conditions and expected developments at the date the statements are made, such as current and future market conditions, the current and future regulatory environment and future approvals and permits. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements, including general business and economic conditions, changes in laws and regulations, product demand, changes in prices of required commodities, competition, the effects of and responses to the COVID-19 pandemic and other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual information form dated April 15, 2020 (the “AIF“) and filed with Canadian securities regulators available on the Company’s issuer profile on SEDAR at www.sedar.com. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.

SOURCE Avicanna Inc.

Are you an investor in Pharmacielo $PCLO.ca Check out our recent interview with Avicanna $AVCN.ca

Posted by AGORACOM-JC at 5:20 PM on Wednesday, August 5th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg
  • A Full Pipeline Of Pharmaceuticals In Various Stages Of Trials To Address Dermatology, Psychiatry, Neurology, Pain and Oncology
  • 3 Products Already As Far As PHASE 2

If you’re an investor in Aurora Cannabis $ACB Check out our recent interview with Avicanna $AVCN.ca

Posted by AGORACOM-JC at 5:25 PM on Tuesday, August 4th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

MEDICAL CANNABIS

  • Medical Cannabis 2.0 – Superior Products To Products Currently On The Market
    • Evidence Backed Medical Cannabis So Doctors Can Prescribe With Confidence
  • Launch Across Canada Immanent
  • Exclusive Distribution Through Online Store Of Shoppers Drug Mart
  • Global Distribution Through US, U.K, Australia, Colombia and Canada In H2 2020

If you’re an investor in Canopy Growth $WEED.ca Check out our recent interview with Avicanna $AVCN.ca

Posted by AGORACOM-JC at 4:44 PM on Friday, July 31st, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

CONSUMER RETAIL – COSMETICS

  • The Only Known CBD Cosmetics Backed By Clinical Trials
  • Full Line Of High End CBD Based Skin Care Products
  • Already Commercializing In Colombia
  • Global Distribution In H2 2020 In United States, Europe and Canada
    • Canadian Distribution Through Shoppers Drug Mart

VIDEO – Avicanna $AVCN.ca Is Delivering The Vertically Integrated #Cannabis Company That Others Failed To $WEED.ca $TLRY $HARV.ca

Posted by AGORACOM-JC at 4:50 PM on Thursday, July 30th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

The Tortoise and the Hare is the famous fable most of us grew up with that teaches this very important lesson – you can be more successful by doing things slowly and steadily than by acting quickly and carelessly.  Said another way, slow and steady wins the race.

Avicanna (AVCN:TSX) (AVCNF:OTCQB) (0NN:Frankfurt) is the Hare.  The company very few paid attention to because it started off the Cannabis stock market race slowly and surely, while all the other rabbits ran so quickly to win the race that they ended up tripping over themselves or getting so exhausted they couldn’t finish the race.

You know who those companies are.  All flash, big promises, big promotions, big stock prices ….. and HUGE disappointments.

Avicanna has surpassed all of them and is starting to pick up speed.  When Avicanna says it is vertically integrated, it isn’t a buzz word, it’s the real story with 4 fully operating divisions that are hitting on all cylinders including, Tier-1 National Partnerships, Global Distribution, Medical Acceptance and History Making Sales.

Here is a snapshot of what we are referring to, followed by an incredible interview with CEO, Aras Azadian, whose quiet confidence sends the following powerful message – 

“Watch Us Cross The Finish Line”

CONSUMER RETAIL – COSMETICS

  • The Only Known CBD Cosmetics Backed By Clinical Trials
  • Full Line Of High End CBD Based Skin Care Products
  • Already Commercializing In Colombia
  • Global Distribution In H2 2020 In United States, Europe and Canada
    • Canadian Distribution Through Shoppers Drug Mart

MEDICAL CANNABIS

  • Medical Cannabis 2.0 – Superior Products To Products Currently On The Market
    • Evidence Backed Medical Cannabis So Doctors Can Prescribe With Confidence
  • Launch Across Canada Immanent
  • Exclusive Distribution Through Online Store Of Shoppers Drug Mart
  • Global Distribution Through US, U.K, Australia, Colombia and Canada In H2 2020

     PHARMACEUTICALS

  • A Full Pipeline Of Pharmaceuticals In Various Stages Of Trials To Address Dermatology, Psychiatry, Neurology, Pain and Oncology
  • 3 Products Already As Far As PHASE 2

   CULTIVATION

  • 500,000 Sq Ft Of Low Cost and USDA certified Organic Cannabis Cultivation In Colombia
  • First Ever Export Of Feminized Hemp Seeds From Colombia (To United States). 7,000,000 Seeds For $380,000
  • Additional 75,000,000 Seeds Available For Export In Several Pending Transactions 

Watch this interview or listen by Podcast on AppleGoogleSpotify or your favourite podcaster.

Avicanna $AVCN.ca announces the award of two Canadian government NSERC grants: 1) Cannabinoid-based pharmaceutical formulations for the treatment of COVID-19 in collaboration with the University of Toronto; and, 2) Evaluation of cannabinoids for reversing cannabis-based toxicosis in collaboration with the University of Guelph $CRDL.ca $PCLO.ca

Posted by AGORACOM-JC at 8:00 AM on Friday, July 24th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

In addition to a recent MITACS award, Dr. Christine Allen, a Professor at the University of Toronto, was awarded an NSERC Alliance grant for development of cannabinoid-based pharmaceutical formulations for the treatment of COVID-19 induced lung inflammation

Avicanna further expands its existing neurobiological research collaboration with Dr. Jibran Khokhar, a Professor at the University of Guelph, with a 2-year NSERC Alliance grant to investigate the neural basis of cannabis-induced toxicosis

The two NSERC grants leverage the proven track record of Avicanna, the University of Toronto and the University of Guelph in the research and clinical development of cannabinoid-based medicines

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/

TORONTO, July 24, 2020 – Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that the Company’s research collaborators have received two independent peer-reviewed grants from the Natural Sciences and Engineering Research Council of Canada (“NSERC“). The NSERC Alliance grants will be used to expand the investigators’ collaborative research with Avicanna.

For the past three years, Dr. Christine Allen’s research group (CARG) in the Leslie Dan Faculty of Pharmacy at the University of Toronto has supported the development and optimization of Avicanna’s cannabinoid-based products including commercial cosmetics (Pura H&W) and medical cannabis (Rho Phyto) product lines and the pharmaceutical pipeline that is currently under clinical investigation.  Dr. Allen will now leverage a recent MITACS award in addition to this NSERC Alliance grant in collaboration with Avicanna to develop a cannabinoid-based formulation for treatment of COVID-19 related lung inflammation.

A second NSERC Alliance grant was awarded to Dr. Jibran Khokhar, Assistant Professor at the University of Guelph, who has an extensive track-record in behavioural pharmacology and neuroscience. Avicanna’s research program with Dr. Khokhar focuses on evaluating a variety of cannabinoids in several preclinical models of human psychiatric conditions including mental health disorders such as anxiety, depression, and PTSD. The NSERC grant was awarded to evaluate the neurobiological underpinnings of cannabis toxicosis in a preclinical model, and test the potential efficacy of Avicanna’s naturally-derived cannabinoids and formulations in the treatment of cannabis-induced toxicosis. With the recent changes in the Canadian regulations for Cannabis 2.0 allowing for cannabinoid edibles and vapes, there is concern around an increased risk for adverse events arising from accidental high-dose cannabis ingestion. Thus, this two-year project will determine the behavioural and neural correlations of cannabis-induced toxicosis and the effects of cannabinoids for counteracting cannabis-induced toxicosis.

Dr Jibran Khokhar, commented, “This research is extremely timely with the new Cannabis 2.0 regulations and the increased risk for cannabis-induced toxicosis. I am thankful to NSERC and Avicanna for support of this important research that will have an impact in our understanding of the neurobiological underpinnings of, and provide novel treatment avenues to treat, adverse events related to high-dose cannabis exposures.”

About Avicanna Inc.

Avicanna is an Ontario, Canada based corporation focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products through its two main business segments, cultivation and research and development.

Avicanna’s two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia are the base for Avicanna’s cultivation activities. These two companies are licensed to cultivate and process cannabis for the production of cannabis extracts and purified cannabinoids including cannabidiol (CBD) and tetrahydrocannabinol (THC).

Avicanna’s research and development business is primarily conducted out of Canada at its headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto. Avicanna’s scientific team develops products, and Avicanna has also engaged the services of researchers at the Leslie Dan Faculty of Pharmacy at the University of Toronto for the purpose of optimizing and improving upon its products.

Avicanna’s research and development and cultivation activities are focused on the development of its key products, including plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics, and Extracts (defined as plant-derived cannabinoid extracts and purified cannabinoids, including distillates and isolates), with a goal of eventually having these products manufactured and distributed through various markets.

Stay Connected

For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email [email protected].

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and includes statements with respect to the ability of the Company and CARG to develop cannabinoid-based pharmaceutical formulations to treat COVID-19 induced lung inflammation, the ability of the Company to develop cannabinoid-based pharmaceutical products, the results of the two-year project with the University of Guelph determining the behavioural and neural correlations of cannabis-induced toxicosis and the effect of cannabinoids to counteract cannabis-induced toxicosis. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated April 15, 2020, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com.

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

SOURCE Avicanna Inc.

You’re Invited To The 3rd Annual Avicanna $AVCN.ca Symposium On July 21st – REGISTER NOW! $GWPH $CRDL.ca $PCLO.ca

Posted by AGORACOM-JC at 5:14 PM on Monday, July 20th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

(TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN)

Avicanna is a Canadian vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global market place

REGISTER NOW!

WHY AVICANNA?

When we say vertically integrated, we mean it.  Avicanna has 4 fully operating divisions to address the entire market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when Avicanna offers you exposure to the entire vertical.

CONSUMER RETAIL – COSMETICS

  • The Only Known CBD Cosmetics Backed By Clinical Trials
  • Full Line Of High End CBD Based Skin Care Products
  • Already Commercializing In Colombia
  • Global Distribution In H2 2020 In United States, Europe and Canada
    • Canadian Distribution Through Shoppers Drug Mart

MEDICAL MARIJUANA

  • Medical Cannabis 2.0 – Superior Products To Products Currently On The Market
    • Evidence Backed Medical Cannabis So Doctors Can Prescribe With Confidence
  • Launch Across Canada Immanent
  • Exclusive Distribution Through Online Store Of Shoppers Drug Mart
  • Global Distribution Through US, U.K, Australia, Colombia and Canada In H2 2020

     PHARMACEUTICALS

  • A Full Pipeline Of Pharmaceuticals In Various Stages Of Trials To Address Dermatology, Psychiatry, Neurology, Pain and Oncology
  • 3 Products Already As Far As PHASE 2

   CULTIVATION

  • 500,000 Sq Ft Of Low Cost and USDA certified Organic Cannabis Cultivation In Colombia
  • First Ever Export Of Feminized Hemp Seeds From Colombia (To United States). 7,000,000 Seeds For $380,000
  • Additional 75,000,000 Seeds Available For Export In Several Pending Transactions 

Click below to register

Avicanna $AVCN.ca Announces Participation in a Medical #Cannabis Real-World Evidence Research Study Led by the University Health Network in Partnership with Medical Cannabis by #Shoppers™ using its Rho Phyto™ Advanced Medical Cannabis Formulary of Products

Posted by AGORACOM-JC at 8:10 AM on Wednesday, July 15th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg
  • Rho Phyto portfolio contains a full formulary of products including oil drops, sublingual sprays, capsules, and topicals that have controlled dosing, enhanced absorption and stability studies supported by pre-clinical data which will be available exclusively on the Medical Cannabis by Shoppers™ online portal by the end of July 2020.
  • First-of-its-kind Canadian study is led by Dr. Hance Clarke, Director of Pain Services at Toronto General Hospital, and will examine the efficacy of a select group of medical cannabis products including Avicanna’s Rho Phyto line of products on patient reported outcomes of pain, sleep and anxiety.
  • This specific study is aligned and in parallel with Avicanna’s comprehensive clinical program of other real-world evidence studies involving the Rho Phyto products and clinical trials on its pharmaceutical pipeline with world-class, Toronto-based medical institutions.

TORONTO, July 15, 2020 – Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce that its Rho Phyto™ product line of advanced medical cannabis products will be the subject of a Medical Cannabis Real-World Evidence study (“MC-RWE Study“) led by Dr. Hance Clarke of the University Health Network (“UHN“) in Toronto, Canada. The Rho Phyto products were developed in accordance with the recent Health Canada Cannabis 2.0 regulations that allow for more advanced, higher quality, medical cannabis product offerings. These products have been tested for prolonged stability, enhanced absorption, controlled delivery and other properties, in collaboration with Dr. Christine Allen’s research group at the Leslie Dan Faculty of Pharmacy, University of Toronto.

The Rho Phyto medical cannabis product line is a full formulary that includes sublingual sprays, oil drops, capsules, and topicals of various cannabinoid ratios, namely THC and CBD. By offering a variety of delivery systems, the medical community has the possibility to select the appropriate Rho Phyto product to suit a range of medical conditions such as pain relief, which may require either a fast onset of action or prolonged duration of effect over the course of treatment. The products are manufactured under good manufacturing practice (“GMP“) in partnership with MediPharm Labs Inc. to ensure batch-to-batch consistency and high-quality products. The manufacture of the Rho Phyto products in accordance with GMP standard allows for data derived from this MC-RWE Study to provide early insights into Avicanna’s ongoing and future directions of pharmaceutical development. Avicanna remains committed to patient safety and product consistency which is why all products subject to the MC-RWE Study are tested by Sigma Analytical and tracked by TruTrace Blockchain Technologies.

Dr. Justin Grant, Avicanna’s Executive Vice President of Scientific Affairs commented, “After 3 years of collaborating with world-class Toronto-based researchers and clinicians including those at the University of Toronto and UHN, we are excited to offer the most consistent formulary of advanced medical cannabis products to prescribers and principal investigators, including Dr. Clarke, to further demonstrate the potential therapeutic efficacy of cannabinoids.”

Avicanna’s Rho Phyto products will be exclusively available to patients through the Medical Cannabis by Shoppers online portal in addition to UHN clinicians through the MC-RWE Study by the end of July 2020. Additionally, Avicanna and Medical Cannabis by Shoppers are co-hosting a medical symposium in line with the launch of the Rho Phyto product line entitled, “MEDICAL CANNABIS 2.0: Advancements in Cannabinoid Research, Product Offerings and Patient Access“. The symposium will be held on a virtual platform on July 21, 2020 and will include Dr Clarke’s presentation “Real World Evidence and The Future of Medical Cannabis / Cannabinoid medicine for Pain Management” that will provide further insights on the MC-RWE Study. For registration and more information please visit (https://www.avicanna.com/symposium/).

About Avicanna Inc.

Avicanna is an Ontario, Canada based corporation focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products through its two main business segments, cultivation and research and development.

Avicanna’s two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia are the base for Avicanna’s cultivation activities. These two companies are licensed to cultivate and process cannabis for the production of cannabis extracts and purified cannabinoids including cannabidiol (CBD) and tetrahydrocannabinol (THC).

Avicanna’s research and development business is primarily conducted out of Canada at its headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto. Avicanna’s scientific team develops products, and Avicanna has also engaged the services of researchers at the Leslie Dan Faculty of Pharmacy at the University of Toronto for the purpose of optimizing and improving upon its products.

Avicanna’s research and development and cultivation activities are focused on the development of its key products, including plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics, and Extracts (defined as plant-derived cannabinoid extracts and purified cannabinoids, including distillates and isolates), with a goal of eventually having these products manufactured and distributed through various markets.

Stay Connected

For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email [email protected].

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and includes statements with respect to the Rho Phyto products benefiting patients managing a range of medical conditions, the data derived from the MC-RWE Study providing the Company with early insights into Avicanna’s ongoing and future directions of pharmaceutical development, and the Rho Phyto products being available to patients through the Medical Cannabis by Shoppers online portal and UHN clinicians by end of July 2020. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated April 15, 2020, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com.

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

SOURCE Avicanna Inc.